| Literature DB >> 34159863 |
Ari Voutilainen1, Christina Brester2, Mikko Kolehmainen2, Tomi-Pekka Tuomainen1.
Abstract
BACKGROUND: We carried out this study to demonstrate the effects of outcome sensitivity, participant exclusions, and covariate manipulations on results of the epidemiological analysis of coronary heart disease (CHD) and its behaviour-related risk factors.Entities:
Keywords: Categorical covariate; continuous covariate; coronary heart disease; exclusion criterion; outcome sensitivity
Year: 2021 PMID: 34159863 PMCID: PMC8231358 DOI: 10.1080/07853890.2021.1921838
Source DB: PubMed Journal: Ann Med ISSN: 0785-3890 Impact factor: 4.709
Baseline characteristics (the total column) and numbers of study participants with the following conditions diagnosed during the follow-up: any cardiovascular disease (CVD), coronary heart disease (CHD), a myocardial infarction (MI) or unstable angina (UA), and a fatal acute myocardial infarction (AMI).
| Conditions and events diagnosed during the follow-up | |||||
|---|---|---|---|---|---|
| Characteristic | Total | CVD | CHD | MI or UA | AMI |
| 1592 | 1181 | 730 | 502 | 136 | |
| CVD, excluding hypertension, | 672 (42) | 542 (46) | 375 (51) | 260 (52) | 83 (61) |
| Use of hypertension medication, | 381 (24) | 318 (27) | 240 (33) | 168 (34) | 58 (43) |
| Diabetes, | 77 (4.8) | 61 (5.2) | 47 (6.4) | 41 (8.2) | 10 (7.4) |
| Use of cholesterol medication, | 9 (0.6) | 9 (0.8) | 8 (1.1) | 5 (1.0) | 2 (1.5) |
| Cigarette-yeara, mean (SD) | 336 (392) | 339 (402) | 356 (403) | 387 (428) | 431 (478) |
| Never-smokers, | 517 (33) | 377 (32) | 217 (30) | 133 (27) | 34 (25) |
| Former smokers, | 572 (36) | 443 (38) | 274 (38) | 196 (39) | 42 (31) |
| Current smokers, | 503 (32) | 361 (31) | 239 (33) | 173 (35) | 60 (44) |
| Alcohol, grams/week, mean (SD) | 71 (141) | 66 (105) | 62 (92) | 64 (96) | 75 (100) |
| No risk, ≤ 1 portion/week, | 604 (38) | 449 (38) | 285 (39) | 186 (37) | 53 (39) |
| Moderate risk, ≤ 3 portions/day, | 906 (57) | 676 (57) | 415 (57) | 295 (59) | 75 (55) |
| High risk, > 3 portions/day, | 82 (5.2) | 56 (4.7) | 30 (4.1) | 21 (4.2) | 8 (5.9) |
| Body Mass Index (BMI), mean (SD) | 27 (3.7) | 27 (3.7) | 27 (3.7) | 27 (3.7) | 28 (4.5) |
| Normal weight, BM | 480 (30) | 324 (27) | 183 (25) | 118 (24) | 35 (26) |
| Overweight, BMI 25.0 − 29.9 kg/m2, | 830 (52) | 622 (53) | 400 (55) | 278 (55) | 60 (44) |
| Obese, BM | 282 (18) | 235 (20) | 147 (20) | 106 (21) | 41 (30) |
| Physical activityb, kcal/day, mean (SD) | 2380 (899) | 2377 (886) | 2349 (888) | 2326 (877) | 2381 (987) |
| Moderate, PALc < 2.00, | 293 (18) | 222 (19) | 144 (20) | 101 (20) | 29 (21) |
| Vigorous, PAL 2.00 − 2.40, | 507 (32) | 377 (32) | 236 (33) | 165 (33) | 41 (30) |
| Extreme, PA | 774 (49) | 571 (49) | 341 (47) | 229 (46) | 65 (48) |
| No data available, | 18 | 11 | 9 | 7 | 1 |
| Systolic blood pressure, mean (SD) | 136 (18) | 137 (18) | 136 (18) | 137 (19) | 139 (18) |
| Desirable, < 120 mmHg, | 269 (17) | 186 (16) | 122 (17) | 89 (18) | 17 (13) |
| Borderline, 120 − 139 mmHg, | 763 (48) | 552 (47) | 331 (45) | 213 (42) | 61 (45) |
| High, ≥ 140 mmHg, | 560 (35) | 443 (38) | 277 (38) | 200 (40) | 58 (43) |
| Fasting blood glucose, mean (SD) | 4.8 (1.2) | 4.9 (1.3) | 4.9 (1.4) | 5.0 (1.5) | 5.1 (1.6) |
| Desirable, < 5.6 mmol/L, | 1435 (90) | 1056 (89) | 636 (87) | 432 (86) | 112 (82) |
| Borderline, 5.6 − 6.9 mmol/L, | 96 (6.0) | 71 (6.0) | 53 (7.3) | 40 (8.0) | 12 (8.8) |
| High, > 6.9 mmol/L, | 61 (3.8) | 54 (4.6) | 41 (5.6) | 30 (6.0) | 12 (8.8) |
| Serum total cholesterol, mean (SD) | 6.0 (1.1) | 6.0 (1.1) | 6.1 (1.2) | 6.2 (1.2) | 6.3 (1.2) |
| Desirable, < 5.2 mmol/L, | 383 (24) | 270 (23) | 151 (21) | 93 (19) | 25 (19) |
| Borderline, 5.2 − 6.2 mmol/L, | 607 (38) | 443 (38) | 274 (38) | 190 (38) | 46 (34) |
| High, > 6.2 mmol/L, | 602 (38) | 468 (40) | 305 (42) | 219 (44) | 65 (48) |
Cigarettes per day times years of smoking.
Total energy expenditure (TEE) minus basal energy expenditure (BEE).
Physical activity level, TEE divided by BEE.
Figure 1.Procedure for statistical analyses. First, analysis sets (AS) 1 and 2 studied effects of participants exclusions on analysis results prospectively; the exclusions were based on baseline characteristics (Criteria A − C). Second, AS 1 and 2 studied effects of covariate manipulations (continuous vs. categorical) on analysis results. Third, AS 3 studied effects of participant exclusions on analysis results retrospectively; the exclusions were based on outcomes (Scenarios Y and Z). Fourth, all AS studied effects of outcome sensitivity on analysis results (see Tables 2–4).
Hazard ratios and corresponding p-values of any cardiovascular disease (CVD), coronary heart disease (CHD), a myocardial infarction (MI) or unstable angina (UA), and a fatal acute myocardial infarction (AMI) with respect to one unit (1 U) or one standard deviation (1 D) increase in seven factors used as continues covariates in the Cox proportional-hazards model.
| CVD | CHD | MI or UA | AMI | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Covariate | 1U | 1D | 1U | 1D | 1U | 1D | 1U | 1D | ||||
| A. Smokinga | 1.00 | 1.27 | .16 | |||||||||
| B. Smoking | 1.00 | 1.18 | .28 | |||||||||
| C. Smoking | ||||||||||||
| A. ACb | 1.00 | 1.05 | .32 | 1.00 | 1.01 | .89 | 1.00 | 1.01 | .87 | 1.00 | 1.15 | .39 |
| B. AC | 1.00 | 1.05 | .30 | 1.00 | 1.00 | .96 | 1.00 | 0.97 | .68 | 1.00 | 1.11 | .48 |
| C. AC | 1.00 | 1.00 | .95 | 1.00 | 0.94 | .24 | 1.00 | 0.95 | .39 | 1.00 | 1.06 | .58 |
| A. BMIc | 1.04 | 1.13 | .05 | 1.03 | 1.12 | .14 | 1.08 | 1.29 | .06 | |||
| B. BMI | ||||||||||||
| C. BMI | ||||||||||||
| A. PALd | 1.00 | 0.99 | .78 | 1.00 | 0.95 | .43 | 1.00 | 0.96 | .64 | 1.00 | 1.14 | .42 |
| B. PAL | 1.00 | 0.98 | .66 | 1.00 | 0.93 | .25 | 1.00 | 0.94 | .43 | 1.00 | 1.15 | .36 |
| C. PAL | 1.00 | 0.90 | .28 | |||||||||
| A. SBPe | 1.00 | 1.05 | .44 | 1.00 | 1.03 | .73 | 1.01 | 1.18 | .32 | |||
| B. SBP | 1.01 | 1.09 | .15 | 1.01 | 1.09 | .21 | 1.01 | 1.24 | .14 | |||
| C. SBP | 1.01 | 1.16 | .09 | |||||||||
| A. FBGf | ||||||||||||
| B. FBG | ||||||||||||
| C. FBG | ||||||||||||
| A. STCg | 1.04 | 1.04 | .34 | 1.18 | 1.19 | .30 | ||||||
| B. STC | 1.03 | 1.04 | .42 | 1.22 | 1.24 | .11 | ||||||
| C. STC | ||||||||||||
Note. A refers to a dataset excluding CVD, diabetes, and high total cholesterol at baseline (n = 794). B refers to a dataset excluding CVD, except for hypertension, at baseline (n = 920). C refers to a dataset with no exclusions (n = 1592). Bold font indicates a statistically significant HR.
Cigarettes per day times years of smoking.
Alcohol consumption grams/week.
Body Mass Index, weight in kg divided by the square of height in m.
Physical activity level, total energy expenditure minus basal, in kcal per day.
Systolic blood pressure in mmHg.
Fasting blood glucose in mmol/L.
Serum total cholesterol in mmol/L.
Hazard ratios (HR), probabilities (P), and corresponding p-values of any cardiovascular disease (CVD), coronary heart disease (CHD), a myocardial infarction (MI) or unstable angina (UA), and a fatal acute myocardial infarction (AMI) with respect to seven factors used as categorical covariates in the Cox proportional-hazards model.
| CVD | CHD | MI or UA | AMI | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Covariate | HR | P | HR | P | HR | P | HR | P | ||||
| A. Former smoker | 1.07 | 0.52 | .53 | 1.15 | 0.53 | .35 | 0.76 | 0.43 | .51 | |||
| B. Former smoker | 1.11 | 0.53 | .30 | 1.19 | 0.54 | .20 | 0.72 | 0.42 | .38 | |||
| C. Former smoker | 1.09 | 0.52 | .71 | |||||||||
| A. Current smoker | ||||||||||||
| B. Current smoker | ||||||||||||
| C. Current smoker | ||||||||||||
| A. ACa 13 − 252 | 1.05 | 0.51 | .64 | 0.95 | 0.49 | .68 | 0.98 | 0.49 | .92 | 0.63 | 0.39 | .18 |
| B. AC 13 − 252 | 1.04 | 0.51 | .68 | 0.90 | 0.47 | .35 | 0.97 | 0.49 | .82 | 0.84 | 0.46 | .58 |
| C. AC 13 − 252 | 1.03 | 0.51 | .64 | 0.90 | 0.47 | .17 | 0.96 | 0.49 | .66 | 0.80 | 0.44 | .22 |
| A. AC >252 | 1.29 | 0.56 | .30 | 1.13 | 0.53 | .73 | 1.05 | 0.51 | .92 | 1.48 | 0.60 | .60 |
| B. AC >252 | 1.20 | 0.55 | .41 | 0.94 | 0.48 | .85 | 0.86 | 0.46 | .72 | 1.19 | 0.54 | .82 |
| C. AC >252 | 1.16 | 0.54 | .31 | 0.91 | 0.48 | .64 | 0.98 | 0.49 | .93 | 1.23 | 0.55 | .59 |
| A. BMIb 25.0 − 29.9 | 1.14 | 0.53 | .20 | 1.19 | 0.54 | .21 | 1.33 | 0.57 | .09 | 0.90 | 0.47 | .78 |
| B. BMI 25.0 − 29.9 | 1.18 | 0.54 | .07 | 1.27 | 0.56 | .06 | 0.93 | 0.48 | .84 | |||
| C. BMI 25.0 − 29.9 | 1.04 | 0.51 | .86 | |||||||||
| A. BMI ≥30.0 | 1.47 | 0.60 | .12 | |||||||||
| B. BMI ≥30.0 | ||||||||||||
| C. BMI ≥30.0 | ||||||||||||
| A. PALc Vigorous | 1.05 | 0.51 | .73 | 0.94 | 0.48 | .73 | 0.93 | 0.48 | .74 | 0.79 | 0.44 | .63 |
| B. PAL Vigorous | 1.07 | 0.52 | .59 | 0.98 | 0.49 | .89 | 0.99 | 0.50 | .96 | 1.14 | 0.53 | .78 |
| C. PAL Vigorous | 0.91 | 0.48 | .24 | 0.86 | 0.46 | .17 | 0.84 | 0.46 | .19 | 0.72 | 0.42 | .18 |
| A. PAL Extreme | 1.02 | 0.50 | .85 | 0.89 | 0.47 | .46 | 0.89 | 0.47 | .56 | 1.06 | 0.51 | .90 |
| B. PAL Extreme | 1.03 | 0.51 | .79 | 0.87 | 0.47 | .34 | 0.89 | 0.47 | .52 | 1.31 | 0.57 | .54 |
| C. PAL Extreme | 0.72 | 0.42 | .16 | |||||||||
| A. SBPd 120 − 139 | 1.11 | 0.53 | .38 | 0.99 | 0.50 | .96 | 0.89 | 0.47 | .57 | 1.98 | 0.66 | .22 |
| B. SBP 120 − 139 | 1.16 | 0.54 | .20 | 1.02 | 0.50 | .90 | 0.87 | 0.47 | .45 | 2.26 | 0.69 | .13 |
| C. SBP 120 − 139 | 1.12 | 0.53 | .20 | 0.96 | 0.49 | .68 | 0.84 | 0.46 | .18 | 1.24 | 0.55 | .44 |
| A. SBP ≥140 | 1.17 | 0.54 | .39 | 1.02 | 0.50 | .95 | 2.15 | 0.68 | .19 | |||
| B. SBP ≥140 | 1.20 | 0.55 | .27 | 1.06 | 0.51 | .79 | 2.71 | 0.73 | .07 | |||
| C. SBP ≥140 | 1.13 | 0.53 | .28 | 1.09 | 0.52 | .52 | 1.48 | 0.60 | .18 | |||
| A. FBGe 5.6 − 6.9 | 1.51 | 0.60 | .07 | 1.67 | 0.63 | .08 | 1.91 | 0.66 | .05 | 0.78 | 0.44 | .81 |
| B. FBG 5.6 − 6.9 | 1.40 | 0.58 | .08 | 1.12 | 0.53 | .88 | ||||||
| C. FBG 5.6 − 6.9 | ||||||||||||
| A. FBG >6.9 | 2.95 | 0.75 | .16 | |||||||||
| B. FBG >6.9 | 2.73 | 0.73 | .07 | |||||||||
| C. FBG >6.9 | ||||||||||||
| A. STCf 5.2 − 6.2 | 1.16 | 0.54 | .20 | 1.32 | 0.57 | .19 | 1.41 | 0.59 | .47 | |||
| B. STC 5.2 − 6.2 | 1.07 | 0.52 | .52 | 1.23 | 0.55 | .16 | 1.17 | 0.54 | .38 | 0.91 | 0.48 | .82 |
| C. STC 5.2 − 6.2 | 1.09 | 0.52 | .29 | 1.21 | 0.55 | .45 | ||||||
| A. STC >6.2 | 1.19 | 0.54 | .14 | 1.91 | 0.66 | .15 | ||||||
| B. STC >6.2 | 1.07 | 0.52 | .52 | 1.27 | 0.56 | .10 | 1.48 | 0.60 | .28 | |||
| C. STC >6.2 | ||||||||||||
Note. A refers to a dataset excluding CVD, diabetes, and high total cholesterol at baseline (n = 794). B refers to a dataset excluding CVD, except for hypertension, at baseline (n = 920). C refers to a dataset with no exclusions (n = 1592). Bold font indicates a statistically significant HR.
Alcohol consumption in g/week.
Body Mass Index, kg/m2.
Physical activity level, the total energy expenditure divided by the basal energy expenditure, moderate <2.00, extreme >2.40.
Systolic blood pressure in mmHg.
Fasting blood glucose in mmol/L.
Serum total cholesterol in mmol/L.
Hazard ratios (HR), probabilities (P), and corresponding p-values of any cardiovascular disease (CVD), coronary heart disease (CHD), a myocardial infarction (MI) or unstable angina (UA), and a fatal acute myocardial infarction (AMI) with respect to seven factors used as categorical covariates in the Cox proportional-hazards model.
| CVD | CHD | MI or UA | AMI | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Covariate | HR | P | HR | P | HR | P | HR | P | ||||
| Y. Former smoker | 1.06 | 0.51 | .56 | 1.01 | 0.50 | .52 | 1.37 | 0.58 | .09 | 0.75 | 0.43 | .48 |
| Z. Former smoker | 1.17 | 0.54 | .52 | |||||||||
| Y. Current smoker | 1.96 | 0.66 | .07 | |||||||||
| Z. Current smoker | ||||||||||||
| Y. ACa 13 − 252 | 1.08 | 0.52 | .42 | 0.96 | 0.49 | .75 | 1.03 | 0.51 | .88 | 0.69 | 0.41 | .26 |
| Z. AC 13 − 252 | 1.00 | 0.50 | .98 | 0.89 | 0.47 | .14 | 0.90 | 0.47 | .31 | 0.73 | 0.42 | .10 |
| Y. AC > 252 | 1.22 | 0.55 | .42 | 0.86 | 0.46 | .67 | 0.87 | 0.47 | .74 | 1.25 | 0.56 | .77 |
| Z. AC > 252 | 1.19 | 0.54 | .24 | 1.13 | 0.53 | .52 | 1.16 | 0.54 | .53 | 1.42 | 0.59 | .37 |
| Y. BMIb 25.0 − 29.9 | 1.12 | 0.53 | .23 | 1.13 | 0.53 | .36 | 1.21 | 0.55 | .26 | 0.83 | 0.45 | .62 |
| Z. BMI 25.0 − 29.9 | 1.13 | 0.53 | .59 | |||||||||
| Y. BMI ≥ 30.0 | 1.23 | 0.55 | .29 | 1.17 | 0.54 | .52 | 1.97 | 0.66 | .13 | |||
| Z. BMI ≥ 30.0 | ||||||||||||
| Y. PALc Vigorous | 1.01 | 0.50 | .95 | 0.94 | 0.48 | .70 | 0.92 | 0.48 | .68 | 0.82 | 0.45 | .68 |
| Z. PAL Vigorous | 0.92 | 0.48 | .32 | 0.87 | 0.47 | .20 | 0.85 | 0.46 | .20 | 0.71 | 0.42 | .16 |
| Y. PAL Extreme | 0.97 | 0.49 | .83 | 0.87 | 047 | .41 | 0.86 | 0.46 | .44 | 1.09 | 0.52 | .85 |
| Z. PAL Extreme | 0.86 | 0.46 | .07 | 0.70 | 0.41 | .12 | ||||||
| Y. SBPd 120 − 139 | 1.16 | 0.54 | .21 | 0.97 | 0.49 | .84 | 0.86 | 0.46 | .46 | 1.97 | 0.66 | .22 |
| Z. SBP 120 − 139 | 1.08 | 0.52 | .36 | 0.98 | 0.49 | .86 | 0.88 | 0.47 | .33 | 1.30 | 0.57 | .35 |
| Y. SBP ≥ 140 | 1.19 | 0.54 | .33 | 1.05 | 0.51 | .82 | 2.02 | 0.67 | .22 | |||
| Z. SBP ≥ 140 | 1.14 | 0.53 | .26 | 1.09 | 0.52 | .54 | 1.54 | 0.61 | .14 | |||
| Y. FBGe 5.6 − 6.9 | 1.12 | 0.53 | .61 | 1.34 | 0.57 | .31 | 1.46 | 0.59 | .25 | 0.57 | 0.36 | .59 |
| Z. FBG 5.6 − 6.9 | ||||||||||||
| Y. FBG > 6.9 | 1.86 | 0.65 | .07 | 1.89 | 0.65 | .39 | ||||||
| Z. FBG > 6.9 | ||||||||||||
| Y. STCf 5.2 − 6.2 | 1.19 | 0.54 | .14 | 1.48 | 0.60 | .06 | 1.50 | 0.60 | .38 | |||
| Z. STC 5.2 − 6.2 | 1.07 | 0.52 | .36 | 1.25 | 0.56 | .08 | 1.11 | 0.53 | .68 | |||
| Y. STC > 6.2 | 1.20 | 0.55 | .12 | 1.93 | 0.66 | .14 | ||||||
| Z. STC > 6.2 | 1.54 | 0.61 | .07 | |||||||||
Note. Y refers to a dataset with no exclusions for study participants with no CVD during the follow-up (n = 411) and excluding CVD, diabetes, and high total cholesterol at baseline for study participants with CVD during the follow-up (n = 546). Z refers to a dataset excluding CVD, diabetes, and high total cholesterol at baseline for study participants with no CVD during the follow-up (n = 248) and no exclusions for study participants with CVD during the follow-up (n = 1182). Bold font indicates a statistically significant HR.
Alcohol consumption (g/week).
Body Mass Index (kg/m2).
Physical activity level, the total energy expenditure divided by the basal energy expenditure, moderate <2.00, extreme >2.40.
Systolic blood pressure (mmHg).
Fasting blood glucose (mmol/L).
Serum total cholesterol (mmol/L).
Results of sample size calculations regarding the main outcome of this study, coronary heart disease (CHD), with respect to Criterion A that excluded study participants according to conditions at baseline.
| Observed | Required | ||||
|---|---|---|---|---|---|
| CHD | No CHD | ||||
| Smoking: Never-smoker (Reference) | 296 | 100 (34) | 196 (66) | 4213 | 1140 |
| Smoking: Former smoker | 270 | 101 (37) | 169 (63) | 3792 | |
| Smoking: Current smoker | 228 | 92 (40) | 136 (60) | 912 | |
| Alcohol consumption: Light | 308 | 112 (36) | 196 (64) | 2854 | |
| Alcohol consumption: Moderate | 454 | 172 (38) | 282 (62) | 1843 | |
| Alcohol consumption: Heavy (Reference) | 32 | 9 (28) | 23 (72) | 184 | 285 |
| Normal weight (Reference) | 278 | 94 (34) | 184 (66) | 1886 | 794 |
| Overweight | 415 | 156 (38) | 259 (62) | 2829 | |
| Obese | 101 | 43 (43) | 58 (57) | 318 | |
| Physical activity: Moderate | 144 | 55 (38) | 89 (62) | 6390 | |
| Physical activity: Vigorous | 251 | 93 (37) | 158 (63) | 29089 | |
| Physical activity: Extreme (Reference) | 391 | 141 (36) | 250 (64) | 48481 | 15975 |
| Systolic blood pressure: Desirable | 141 | 52 (37) | 89 (63) | 5860 | |
| Systolic blood pressure: Prehypertension (Reference) | 404 | 140 (35) | 264 (65) | 19535 | 1364 |
| Systolic blood pressure: Hypertension | 249 | 101 (41) | 148 (59) | 818 | |
| Fasting blood glucose: Desirable (Reference) | 753 | 269 (36) | 484 (64) | 5945 | 239 |
| Fasting blood glucose: Prediabetes | 31 | 14 (45) | 17 (55) | 238 | |
| Fasting blood glucose: Diabetes | 10 | 10 (100) | 0 (0) | 2 | |
| Serum total cholesterol: Desirable (Reference) | 190 | 55 (29) | 135 (71) | 432 | 177 |
| Serum total cholesterol: Pre-hypercholesterolaemia | 315 | 118 (37) | 197 (63) | 734 | |
| Serum total cholesterol: Hypercholesterolaemia | 289 | 120 (42) | 169 (58) | 266 | |
Note. Required n refers to comparisons across the category in which the proportion of CHD diagnoses during the follow-up was lowest (reference) and other categories applying a predetermined p-value of .05 (α) and a predetermined power of 0.80 (1 − β).